Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Not Applicable

Completed

• Conditions: Non-Small Cell Lung Cancer

• Registration Number: NCT00283478
• Lead Sponsor: Kentuckiana Cancer Institute

Brief Summary

To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.

Detailed Description

RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.

Study Timeline

• Study Start: 2004-05
• Study First Submitted: 2006-01-26
• Study First Submitted QC: 2006-01-26
• Study First Posted: 2006-01-30
• Study Completion: 2007-04
• Status Verified: 2007-10
• Last Update Submitted: 2007-10-30
• Last Update Posted: 2007-10-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
• Karnofsky score 60% or greater
• patients who will be treated with Gemcitabine

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To determine if Iscar improves immune function and quality of life.

Trial Locations

Locations (1)

Kentuckiana Cancer Institute; 🇺🇸 Louisville, Kentucky, United States